Want to see RNAZ full AI Analyst Report?
Top Page
TransCode Therapeutics
(NASDAQ:RNAZ)
Select Model
Select Model
Rating:49Neutral
Price Target:
$11.50
▲(65.23% Upside)
Action:Reiterated
Date:01/24/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and ongoing cash burn), with limited valuation support due to continued losses. Offsetting factors include constructive near-term technical momentum and positive corporate developments around the pipeline and planned Phase 2a work, though high volatility and stretched oscillators temper the technical contribution.
Positive Factors
Delivery platform efficacy (glioblastoma preclinical)
Published murine glioblastoma results demonstrate the company’s delivery platform can systemically deliver antisense payloads to brain tumors and extend survival. This durable technical validation strengthens the platform’s differentiation and supports advancing indications beyond metastatic disease.
Negative Factors
No revenue; widening net losses
Persistent zero revenue with expanding net losses means the company lacks internal revenue-derived funding and must rely on external capital. Over months this increases dilution risk, constrains investment choices, and places pressure on program prioritization and long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Delivery platform efficacy (glioblastoma preclinical)
Published murine glioblastoma results demonstrate the company’s delivery platform can systemically deliver antisense payloads to brain tumors and extend survival. This durable technical validation strengthens the platform’s differentiation and supports advancing indications beyond metastatic disease.
Read all positive factors
TransCode Therapeutics (RNAZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.83M
Dividend YieldN/A
Average Volume (3M)282.59K
Price to Earnings (P/E)―
Beta (1Y)2.64
Revenue GrowthN/A
EPS Growth95.40%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,058,481
10 Day Avg. Volume825,542
30 Day Avg. Volume282,592
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TransCode Therapeutics Business Overview & Revenue Model
Company Description
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead t...
How the Company Makes Money
null...
TransCode Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -42.16K | 0.00 | -534.86K | -516.75K | -98.61K | -42.47K |
| EBITDA | -39.81M | -34.31M | -16.19M | -17.97M | -17.47M | -6.71M |
| Net Income | -40.36M | -34.66M | -16.75M | -18.55M | -17.56M | -6.84M |
Balance Sheet | ||||||
| Total Assets | 157.16M | 162.40M | 7.29M | 5.17M | 7.59M | 22.94M |
| Cash, Cash Equivalents and Short-Term Investments | 12.84M | 17.81M | 5.81M | 2.77M | 4.98M | 20.83M |
| Total Debt | 0.00 | 0.00 | 38.29K | 450.57K | 0.00 | 0.00 |
| Total Liabilities | 12.64M | 152.06M | 9.31M | 3.53M | 4.35M | 2.53M |
| Stockholders Equity | 144.52M | 10.34M | -2.02M | 1.64M | 3.24M | 20.40M |
Cash Flow | ||||||
| Free Cash Flow | -4.99B | -19.52M | -13.36M | -18.11M | -15.86M | -5.52M |
| Operating Cash Flow | -4.99B | -19.52M | -13.34M | -18.07M | -15.76M | -5.27M |
| Investing Cash Flow | -4.44K | -4.44K | -21.76K | -35.61K | -100.92K | -251.82K |
| Financing Cash Flow | 22.67M | 31.52M | 16.40M | 15.91M | 5.99K | 25.52M |
TransCode Therapeutics Technical Analysis
Negative
6.96
Price Trends
6.26
Negative
7.29
Negative
8.45
Negative
Market Momentum
-0.58
Positive
31.86
Neutral
6.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAZ, the sentiment is Negative. The current price of 6.96 is below the 20-day moving average (MA) of 7.26, above the 50-day MA of 6.26, and below the 200-day MA of 8.45, indicating a bearish trend. The MACD of -0.58 indicates Positive momentum. The RSI at 31.86 is Neutral, neither overbought nor oversold. The STOCH value of 6.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAZ.
TransCode Therapeutics Risk Analysis
TransCode Therapeutics disclosed 97 risk factors in its most recent earnings report. TransCode Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TransCode Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $11.35M | -0.96 | -59.30% | ― | -100.00% | 13.00% | |
49 Neutral | $4.83M | -0.09 | -99.39% | ― | ― | 95.40% | |
45 Neutral | $10.19M | -0.28 | -96.39% | ― | ― | 80.68% | |
41 Neutral | $843.07K | -0.03 | 1211.14% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
RNAZ
TransCode Therapeutics
4.22
-7.28
-63.30%
KPRX
Kiora Pharmaceuticals
2.47
-0.03
-1.20%
LYRA
Lyra Therapeutics
0.48
-6.28
-92.96%
INAB
IN8bio
0.96
-1.21
-55.76%
TransCode Therapeutics Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
TransCode Therapeutics Shareholders Approve Key Capital Measures
Positive
Jul 20, 2026
On July 20, 2026, TransCode Therapeutics held its 2026 Annual Meeting of Stockholders, where 52.1% of the company’s voting power was represented, constituting a quorum for business. All proposals presented were approved, reinforcing the comp...
Business Operations and StrategyRegulatory Filings and Compliance
TransCode Therapeutics Updates Preferred Stock Ownership Limits
Positive
Jul 17, 2026
On July 16, 2026, TransCode Therapeutics, Inc. amended and restated the certificate of designation governing its Series C Non-Voting Convertible Preferred Stock, following consent from a majority of Series C holders and approval by its board. The ...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder Meetings
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps
Neutral
Jul 2, 2026
On July 2, 2026, TransCode Therapeutics opened its 2026 Annual Meeting of Stockholders but adjourned it to July 20, 2026, after preliminary results showed all proposals had sufficient support for approval. The postponement was driven by administra...
Business Operations and StrategyProduct-Related Announcements
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
Positive
Jun 18, 2026
On June 18, 2026, TransCode Therapeutics posted an investor presentation outlining its progress across three cancer treatment platforms and highlighting its lead RNA therapeutic candidate, TTX-MC138. The Phase 2a-stage antagomiR targets microRNA-1...
Business Operations and Strategy
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a
Positive
Jun 3, 2026
On June 3, 2026, TransCode Therapeutics reported that its Phase 1a dose-escalation trial of lead RNA-based cancer therapeutic TTX-MC138 met its primary safety endpoint with no dose-limiting toxicities in 16 metastatic cancer patients given 86 tota...
Regulatory Filings and ComplianceShareholder Meetings
TransCode Sets Key Deadlines for 2026 Shareholder Meeting
Neutral
Jun 1, 2026
TransCode Therapeutics said it plans to hold its 2026 annual meeting of stockholders on July 2, 2026, with May 28, 2026, set as the record date for shareholders entitled to notice and voting. The company noted that its 2025 annual meeting occurred...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice
Negative
May 22, 2026
On May 19, 2026, TransCode Therapeutics disclosed that it received a deficiency letter from Nasdaq after reporting stockholders’ equity of about $1.25 million as of March 31, 2026, below the $2.5 million minimum required for continued listin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.